S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)|
|Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington’s Disease Trial|
|OncoGenex to Regain Rights to Custirsen from Teva|
|Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review|
|Teva Reports Third Quarter 2014 Results|
|Teva Provides 2015 Business Outlook|
|Teva Announces Launch of First Generic Celebrex® Capsules in the United States|
|Teva to Host 2015 Business Outlook Conference Call and Webcast on December 11, 2014|
|Teva to Report Fourth Quarter 2014 Financial Results on February 5, 2015|
|Teva Announces Launch of Generic Exforge HCT® Tablets in the United States|
Click above to view more mutual fund data and stats for teva - Teva Pharmaceutical Industries Ltd ADR.